AKT1 and hepatocellular carcinoma: Reduces Nrf2 expression in hepatocellular carcinoma through down-regulation of PI3K-Akt and ERK pathways re-sensitizing cells to doxorubicin [153]Depletes glutathione and enhances doxorubicin-induced cytotoxicity in epithelial cancer cells [69,94]